Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)

Elisabeth H Bel,1 Ana Sousa,2 Louise Fleming,3 Andrew Bush,4 K Fan Chung,5 Jennifer Versnel,6 Ariane H Wagener,1 Scott S Wagers,7 Peter J Sterk,1 Chris H Compton,8 on behalf of the members of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation9

ABSTRACT
Patients with severe refractory asthma pose a major healthcare problem. Over the last decade it has become increasingly clear that, for the development of new targeted therapies, there is an urgent need for further characterisation and classification of these patients. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) consortium is a pan-European public-private collaboration funded by the European Commission Innovative Medicines Initiative of the European Union. U-BIOPRED aims to subphenotype patients with severe refractory asthma by using an innovative systems biology approach. This paper presents the U-BIOPRED international consensus on the definition and diagnosis of severe asthma, aligning the latest concepts in adults as well as in children. The consensus is based on existing recommendations up to 2010 and will be used for the selection of patients for the upcoming U-BIOPRED study. It includes the differentiation between ‘problematic’, ‘difficult’ and ‘severe refractory’ asthma, and provides a systematic algorithmic approach to the evaluation of patients presenting with chronic severe asthma symptoms for use in clinical research and specialised care.

DIAGNOSIS AND DEFINITION OF SEVERE ASTHMA OVER THE LAST 15 YEARS
Various documents proposing different clinical definitions of ‘severe asthma’ in adults and children have been published over the last 15 years by international task forces, workshops, networks and guideline committees.

Adult guidelines
In the Global Initiative for Asthma15 1995 and 2002 updates and the National Asthma Education and Prevention Programme 199716 guidelines, overall asthma severity was primarily based on the patient’s clinical characteristics prior to commencing treatment. Off-treatment severity was classified into intermittent, mild persistent, moderate persistent and severe persistent, based on symptoms, short-acting β2 agonist use, night time awakening and peak expiratory flow or the percentage predicted forced expiratory volume in 1 s (FEV1). This initial classification was used to determine the patient’s initial treatment but did not take into account disease responsiveness to treatment.

In 1999 an ERS Task Force1 defined ‘difficult/ therapy-resistant asthma’ as poorly controlled asthma and a continued requirement for short-acting β2 agonists despite delivery of a reasonable dose of inhaled corticosteroids (ICS) and follow-up by a respiratory specialist for a period of >6 months. During this period, asthma management had to be carried out according to published asthma guidelines.

In 2000 an ATS Workshop2 adopted the term ‘refractory asthma’ and developed a definition by consensus. The definition included one of two major criteria (continuous high-dose ICS or oral corticosteroids for >50% of the time during the previous year), with two out of seven additional minor criteria: requirement of additional controller medications, aspects of disease stability, exacerbations and lung function. This definition was adopted by the NIH/NHLBI-sponsored Severe Asthma Research Program (SARP)17 network.

The European Network for Understanding Mechanisms of Severe Asthma18 defined ‘severe asthma’ in 2003 as confirmed asthma (typical asthma symptoms, reversibility in FEV1 or airway hyper-responsiveness) plus the occurrence of one or
more exacerbations in the previous year despite oral corticosteroids or high-dose ICS.\textsuperscript{13} The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study group\textsuperscript{14} included patients with high use of the healthcare system or high medication use in the past year.

In 2007 an international workshop was organised in Paris to discuss the important questions in severe asthma.\textsuperscript{20} This workshop agreed that a diagnosis of ‘severe asthma’ should be reserved for those patients who have refractory asthma after an extensive re-evaluation of the correct diagnosis, aggravating comorbidities and environmental factors and an appropriate observation period of at least 6 months.

**Paediatric guidelines**

In children there has been a lack of general consensus on the definition of severe asthma. In 2008 an ERS Task Force on Definition, Assessment and Treatment of Wheezing Disorders in Preschool Children\textsuperscript{21} stated that making a diagnosis of asthma in preschool children is unfeasible. Whereas in adults and children >6 years of age there is consensus that asthma is characterised by airway inflammation,\textsuperscript{15} this has been poorly studied in preschool children,\textsuperscript{22} and may be absent in very young children who wheeze.\textsuperscript{23} The Task Force members therefore adopted a symptoms-only descriptive approach for children <6 years of age, and used the terms ‘episodic (viral) wheeze’ to describe children who wheeze intermittently and are well between episodes and ‘multiple-trigger wheeze’ for children who wheeze both during and outside discrete episodes.\textsuperscript{21}

In 2008 the Problematic Severe Asthma in Childhood Initiative (PSACI) group\textsuperscript{24} proposed the use of the term ‘problematic severe asthma’ to describe all school-aged children who, despite regular treatment with ≥800 µg/day budesonide or equivalent of ICS plus a long-acting \( \beta \)-agonist, a leukotriene receptor antagonist or theophylline, have poorly controlled asthma—that is, daily asthma symptoms, recurrent severe asthma exacerbations (or a single near-fatalf asthma attack), persistent airflow obstruction or the necessity for the prescription of chronic oral steroids to achieve control of asthma. ‘Difficult-to-treat asthma’ was defined as asthma where the poor control is due to a wrong diagnosis or comorbidities, the inability and unwillingness to adhere to the prescribed treatment regimens or adverse psychological and environmental factors. ‘Severe therapy-resistant asthma’ was defined by the same group as ‘difficult’ asthma that remains uncontrolled despite attention to and resolution of all these factors.

**SHORTCOMINGS OF PREVIOUS DEFINITIONS ON SEVERE ASTHMA**

When studying the above-mentioned definitions of ‘severe asthma’, it appears that they have been refined and sharpened over the years. After the initial Global Initiative for Asthma 2005\textsuperscript{15} and National Asthma Education and Prevention Programme 1997\textsuperscript{16} guidelines in which overall asthma severity was based on the patient’s clinical characteristics prior to commencing treatment, an assessment of asthma severity in patients on treatment seemed to be necessary.\textsuperscript{25}

The definition of ‘difficult/therapy-resistant asthma’ by the ERS Task Force in 1999\textsuperscript{1} described patients with poorly controlled asthma despite prescription of a reasonable dose of ICS (defined as ≥2000 µg beclometasone or the equivalent dose in adults and ≥800 µg beclometasone or equivalent), and emphasised the need for addressing (1) the diagnosis of asthma; (2) adequate management of asthma; (3) compliance with treatment; (4) identification of exacerbating factors; and (5) exclusion of other diagnoses. Care of the patient by a respiratory specialist for at least 6 months was advisable. The proposed definition of the ERS Task Force was inclusive with the recognition that difficult/therapy-resistant asthma could be due to poor adherence, incorrect inhaler technique, psychological problems and comorbidities. It was also recognised that the definition could be adjusted according to the objectives of any individual research project.

The criteria for ‘refractory asthma’ as determined by the ATS Workshop in 2000\textsuperscript{2} were more strictly defined in terms of the criteria of severity of asthma (≥2 of 7 criteria) in patients who were on high-dose ICS and/or oral corticosteroids for >50% of the time. Moore and colleagues\textsuperscript{27} in their 2007 report on patients with severe asthma in the Severe Asthma Research Project (SARP) using the definition of the ATS Workshop found that the factors that best discriminated mild/moderate from severe asthma (apart from the use of high-dose ICS or oral corticosteroids ≥50% of the time) were the use of multiple controller medications (including long-acting \( \beta \)\(_2\) agonists), ≥3 bursts of oral corticosteroids in the previous year or a history of at least one severe exacerbation requiring hospitalisation during the last year.

The most recent definitions of severe therapy-resistant asthma are the ones proposed by the Paris Workshop in 2007 for adults,\textsuperscript{20} and the PSACI group in 2009 for children.\textsuperscript{26} These definitions distinguished patients with ‘severe refractory asthma’ from those with ‘difficult-to-treat asthma’, the latter presenting with uncontrolled asthma due to other factors than asthma itself, including persistent environmental exposures, aggravating comorbidities, poor adherence and inadequate inhalation technique. This distinction is important because patients with difficult-to-treat asthma may not be candidates for immune suppressive or innovative anti-inflammatory therapies.

Finally, in April 2009 the WHO Consultation on Severe Asthma proposed a global definition of asthma severity which should be applicable in most circumstances in low-, middle- and high-income countries.\textsuperscript{27} Severe asthma was defined as ‘uncontrolled asthma which can result in risk of frequent severe exacerbations (or death) and/or adverse reactions to medications and/or chronic morbidity (including impaired lung function or reduced lung growth in children)’. The WHO Consultation adopted the definitions of ‘severe’ and ‘difficult’ asthma from the Paris Workshop in 2007\textsuperscript{16} and extended it with a third group of patients with ‘untreated’ severe asthma. The latter group is, of course, of major importance in low-income countries where asthma drugs are not readily available to everyone and asthma deaths are still occurring.

**APPROACH TO EVALUATING PATIENTS WITH SEVERE ASTHMA SYMPTOMS**

For a correct diagnosis of severe refractory asthma, it is mandatory that patients who present with severe asthma symptoms or recurrent exacerbations are evaluated in a stepwise manner to address the following issues (figure 1).

**Distinction between severe and uncontrolled asthma**

Severe asthma should be distinguished from uncontrolled asthma. Uncontrolled asthma refers to the extent to which the manifestations of asthma have not been reduced or removed by treatment.\textsuperscript{28} Asthma control incorporates components of current clinical control including symptoms, use of rescue
Figure 1  Algorithm to diagnose a patient with severe refractory asthma. NSAID, non-steroidal anti-inflammatory drug; PEF, peak expiratory flow.

Patient has uncontrolled asthma and/or frequent (>2/yr) asthma exacerbations

Yes  No

Patient has prescription of high dose inhaled corticosteroids* with or without systemic corticosteroids

Yes  No

Patient has a confirmed diagnosis of asthma *

Yes  No

Patient is using inhalers correctly and has received adequate asthma education

Yes  No

Patient is compliant with asthma treatment

Yes  No

Alternative or overlapping diagnoses as primary conditions are excluded

Yes  No

Exposure to sensitizing and non-sensitizing substances in school or workplace are excluded

Yes  No

Exposure to sensitizing or non-sensitizing substances at home are optimally controlled

Yes  No

Drugs that may cause bronchoconstriction are discontinued

Yes  No

Co-morbidities are optimally treated

Yes  No

Patient has been followed and reassessed for at least 6 months

Yes  No

Patient has severe refractory asthma

Yes

*High intensity asthma treatment is defined as:
- ≥1000 mcg/day fluticasone equivalent combined with long acting beta-2-agonists or other controllers (adults)
- ≥500 mcg/day fluticasone equivalent (school-aged children)
- ≥400 mcg/day budesonide equivalent and oral leukotriene receptor antagonists (pre-school children)

* Asthma is confirmed by a history of wheeze either spontaneously or on exertion, as well as variable airflow limitation (in school age and above) by:
- Variability of peak expiratory flow (amplitude %mean of twice daily measurements > 8%)
- Reversibility in FEV1, to 400 mcg inhaled salbutamol (>12% predicted and >200 ml)
- Airway hyperresponsiveness to methacholine (PC20 <8 mg/ml)
- Fall in FEV1 >12% plus >200 ml when tapering treatment (any one or more of inhaled corticosteroids, oral corticosteroids, long- and short acting beta-2 agonists) as long as the patient can tolerate this.
medication and lung function, as well as future risks. Asthma severity is determined by the intensity and phenotype of the underlying disease, both of which may be characterised by pathological and physiological markers. These markers can also be used to estimate future risk of exacerbation or decline in lung function.

Exacerbations are a prominent feature of both poorly controlled and severe asthma. Improving baseline asthma control with ICS can reduce the risk of exacerbations in patients with atopic asthma, but control of daily symptoms does not always imply control of exacerbations. Baseline disease control and exacerbations are most probably driven by different factors.

Adherent to high-intensity asthma treatment
A significant proportion of patients with uncontrolled asthma who are prescribed high doses of ICS do not take their medicines. In a case series, 50% of patients prescribed oral steroids were found to be non-adherent when assessed by plasma prednisone and cortisol concentrations. Also, other studies in adults and children in the USA and the UK showed that overall adherence to ICS was approximately 50%. Adherence to ICS was significantly and negatively correlated with the number of emergency department visits, the number of fills of an oral steroid and the total days’ supply of oral steroid. Eight per cent of patients never filled their ICS prescription. Thus, despite persistent symptoms, many patients choose not to take their prescribed treatment, mainly because they perceive it to be unnecessary, too complex, too expensive in some healthcare systems or because they are concerned about potential adverse effects. In the investigation of patients presenting with severe asthma, it is therefore critical to check adherence, either by measuring serum cortisol, prednisolone and theophylline levels where appropriate, making home visits or checking lists of prescriptions from pharmacies. The Medication Adherence Rating Scale (MARS), a questionnaire that has been developed to estimate patient adherence with treatment, may be a helpful instrument but needs further validation.

Establishing a secure diagnosis of asthma
There are many conditions that may mimic severe refractory asthma, both in children and in adults. Since these conditions do not respond to high-intensity asthma treatment, they may easily be mistaken for severe asthma. A list of common alternative diagnoses and how they should be diagnosed is given in table 1.

<table>
<thead>
<tr>
<th>Trigger factors</th>
<th>Other factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma and rhinosinusitis often coexist and are believed to represent a spectrum of the same disease entity. In particular, in adults, chronic rhinosinusitis and nasal polyps have been shown to be important components of severe steroid-dependent asthma. Nasal symptoms and CT imaging of sinonasal involvement are related to asthma severity, sputum eosinophil</td>
<td></td>
</tr>
</tbody>
</table>
counts and airflow limitation. Medical or surgical treatment of upper airway disease can improve asthma control. Patients with severe asthma should therefore be evaluated and treated for chronic rhinosinusitis, particularly if associated with nasal polyps.

**DEFINING ‘PROBLEMATIC’, ‘DIFFICULT’ AND ‘SEVERE REFRACTORY’ ASTHMA**

By excluding factors that may aggravate or complicate asthma, the subgroup with truly severe refractory asthma can be defined and distinguished from patients with ‘problematic’ or ‘difficult’ asthma.

The term ‘problematic severe asthma’ includes all asthma and asthma-like symptoms that remain uncontrolled despite the prescription of high-intensity asthma treatment. It is an umbrella term that comprises patients with ‘difficult’ asthma as well as patients with ‘severe refractory’ asthma.

The term ‘difficult asthma’ is reserved for asthma that remains uncontrolled despite the prescription of high-intensity asthma treatment due to:
- persistently poor compliance;
- psychosocial factors, dysfunctional breathing, vocal cord dysfunction;
- persistent environmental exposure to allergens or toxic substances;
- untreated or undertreated comorbidities such as chronic rhinosinusitis, reflux disease or obstructive sleep apnoea syndrome.

The term ‘severe refractory asthma’ should be reserved for patients with asthma in whom alternative diagnoses have been excluded, comorbidities have been treated, trigger factors have been removed (if possible) and compliance with treatment has been checked, but still have poor asthma control or frequent (≥2) severe exacerbations per year despite the prescription of

---

Table 1 Tests to distinguish severe asthma from alternative diagnosis that may mimic asthma

<table>
<thead>
<tr>
<th>Routine screening test in adults</th>
<th>Exclusion (if test is normal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Air trapping measured by body plethysmography</td>
<td>Bronchiolitis obliteratorns</td>
</tr>
<tr>
<td>Carbon monoxide diffusion capacity</td>
<td>Emphysema</td>
</tr>
<tr>
<td>Chest HRCT scan</td>
<td>Parenchymal lung disease</td>
</tr>
<tr>
<td>D-dimer</td>
<td>Bronchiolitis obliteratorns</td>
</tr>
<tr>
<td>Suspected alternative or additional diagnoses in adults</td>
<td>Diagnostic test</td>
</tr>
<tr>
<td>Intrabronchial obstruction</td>
<td>Bronchoscopy</td>
</tr>
<tr>
<td>Vocal cord dysfunction</td>
<td>Laryngoscopy during attack</td>
</tr>
<tr>
<td>Dysfunctional breathing/panic attacks</td>
<td>Blood gases during attack</td>
</tr>
<tr>
<td>Recurrent microaspiration</td>
<td>Hyperventilation provocation test</td>
</tr>
<tr>
<td>Cystic fibrosis (CF)</td>
<td>Proximal oesophageal pH measurement</td>
</tr>
<tr>
<td>Allergic bronchopulmonary aspergillosis (ABPA)</td>
<td>Bile salts in bronchoalveolar lavage fluid</td>
</tr>
<tr>
<td>Emphysema</td>
<td>Sweat test</td>
</tr>
<tr>
<td>Hypersensitivity pneumonitis</td>
<td>Aspergillus IgE/precipitins/sputum culture</td>
</tr>
<tr>
<td>Bronchiectasis (including ABPA, CF)</td>
<td>High resolution CT scan</td>
</tr>
<tr>
<td>Recurrent pulmonary embolism</td>
<td>CT pulmonary angiography</td>
</tr>
<tr>
<td>Pulmonary arterial hypertension</td>
<td>Transbronchial or thoracoscopic lung biopsy</td>
</tr>
<tr>
<td>Bronchiolitis</td>
<td></td>
</tr>
<tr>
<td>Sarcoïdosis</td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
</tr>
<tr>
<td>Churg–Strauss syndrome</td>
<td>Biopsy of affected organ(s)</td>
</tr>
<tr>
<td>Suspected alternative or additional diagnoses in children</td>
<td>Diagnostic test</td>
</tr>
<tr>
<td>Structural abnormalities (tracheobronchial malacia, vascular compression/rings, tracheal stenosiswebs, cystic lesions/masses, tumours/lymphadenopathy cardiomegaly)</td>
<td>Fibreoptic bronchoscopy</td>
</tr>
<tr>
<td>Intrabronchial obstruction (eg, inhaled foreign body)</td>
<td>Thorax CT scan</td>
</tr>
<tr>
<td>Vocal cord dysfunction</td>
<td>Rigid bronchoscopy</td>
</tr>
<tr>
<td>Dysfunctional breathing/panic attacks</td>
<td>History, direct observation</td>
</tr>
<tr>
<td>Gastro-oesophageal reflux with/without recurrent microaspiration</td>
<td>History, direct observation</td>
</tr>
<tr>
<td>Cystic fibrosis (CF)</td>
<td>Proximal oesophageal pH measurement</td>
</tr>
<tr>
<td>Immune abnormalities</td>
<td>Bile salts in bronchoalveolar lavage fluid</td>
</tr>
<tr>
<td>Bronchiectasis (including CF, primary ciliary dyskinesia)</td>
<td>Sweat test</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia</td>
<td>Serum immunoglobulins including IgA, G, M and IgG subclasses and vaccine antibody responses (Haemophilus, tetanus and Pneumococcus)</td>
</tr>
<tr>
<td>Bronchiolitis obliteratorns</td>
<td>High resolution CT scan</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia</td>
<td>History of prematurity</td>
</tr>
<tr>
<td>Bronchiolitis obliteratorns</td>
<td>High resolution CT scan</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia</td>
<td>Lung biopsy</td>
</tr>
</tbody>
</table>
high-intensity treatment or can only maintain adequate control when taking systemic corticosteroids and are thereby at risk of serious adverse effects of treatment.

For this definition, poor asthma control is defined according to Juniper et al as a score of $\geq 1.5$ by the 7-item Asthma Control Questionnaire$^{61, 62}$ or an equivalent score by any other standardised asthma control questionnaire. High-intensity treatment in adults is defined as $\geq 1000 \mu g$ daily fluticasone equivalent and/or daily oral corticosteroids combined with long-acting $\beta_2$ agonists or any other controller medication. High-intensity treatment in school age children is defined as $\geq 500 \mu g$ daily fluticasone equivalent or daily oral corticosteroids combined with long-acting $\beta_2$ agonists or any other controller medication. High-intensity treatment in pre-school children is defined as (1) high-dose ICS and oral leukotriene receptor antagonists at the time of viral exacerbations; and/or (2) $\geq 400 \mu g$ daily budesonide equivalent and oral leukotriene receptor antagonists given regularly.

### CLINICAL AND INFLAMMATORY PHENOTYPES OF SEVERE ASTHMA

Although the subgroup of patients with ‘severe refractory asthma’ is less heterogeneous than the group of patients with ‘difficult’ asthma, it is far from homogeneous and may be subdivided into different phenotypes.$^{57, 63}$ Phenotypes have been far less well studied in children, but it is likely that those described below are part of the spectrum of asthma, at least in older children.

From a clinical point of view, three categories of patients with severe asthma seem to be of particular importance: (1) those suffering from frequent severe exacerbations with relatively stable episodes between exacerbations (exacerbation prone asthma); (2) those who develop irreversible airflow obstruction (asthma with fixed airflow obstruction); and (3) those who depend on systemic corticosteroids for daily control of their asthma (steroid-dependent asthma).$^{64}$

Exacerbation-prone asthma accounts for more than 40% of severe asthma in the SARP database,$^{65}$ whereas 60% of patients in the TENOR study had evidence of fixed airflow limitation.$^{66}$ These latter patients are less predisposed to severe exacerbations.$^{67}$ Cohort studies in children suggest that some of these patients may have failed to increase their lung function adequately and fall off their lung function centiles,$^{68}$ but many adult patients with severe asthma show accelerated decline of lung function,$^{69}$ particularly men with recent non-allergic asthma.$^{66, 70}$

A subset of patients with severe asthma requires daily systemic corticosteroids to control their asthma at the cost of serious side effects. This might be due to relative insensitivity to corticosteroids or to involvement of the paranasal sinuses and distal airways in the inflammatory process.

From a pathological point of view, at least two phenotypes of severe asthma have been proposed, each associated with distinct clinical and pathophysiological characteristics. These subtypes include the persistent eosinophilic and non-eosinophilic forms of severe asthma.$^{71}$

Severe asthma with persistent eosinophilia has been put forward by Wenzel and colleagues$^{71}$ and further characterised by others$^{70, 72}$ It is characterised by mixed eosinophilia and neutrophilia in bronchial biopsies and induced sputum despite the use of high-intensity ICS or oral corticosteroid treatment. This type of asthma is associated with severe exacerbations,$^{8, 9}$ sinus disease,$^{72}$ involvement of the peripheral airways,$^{71}$ airflow remodelling$^{73}$ and fixed airflow obstruction,$^{70}$ and responds favourably to treatment with anti-interleukin 5 monoclonal antibody.$^{5, 10}$

In the non-eosinophilic subtype of severe asthma, airway eosinophilia are either absent or suppressed by treatment in the presence of a high level of asthma symptoms.$^{74}$ Airway inflammation in these patients with severe asthma is characterised by an increased percentage of neutrophils.$^{75, 76}$ The potential causal factors that induce airway neutrophilia are numerous, but it is still uncertain whether these cells play an active role in an ongoing airway damaging process.

Different phenotypes of severe asthma have also been proposed in children.$^{77}$ In general, children with severe asthma have no gender bias and are highly atopic with relatively well-preserved lung function. Subphenotyping has been mainly by inflammatory cells in induced sputum. Airway eosinophilia might be characteristic for a separate exacerbating phenotype in which food allergy is a potential factor increasing the severity of exacerbations.$^{78}$

### TOWARDS NEW PHENOTYPES OF SEVERE REFRACTORY ASTHMA

Clinical characterisation of patients by a single clinical characteristic or biomarker is probably not enough to describe the severe asthma phenotypes. The fact that, at a group level, clinical and pathophysiological biomarkers do not correlate strongly with one another$^{79}$ suggests that they add independent information about a patient’s underlying phenotype. New approaches to statistical modelling, such as cluster analysis, may enable a better definition of asthma phenotypes. The first study using factor analysis in asthma supported the idea that different dimensions of the disease—such as airway obstruction, hyper-responsiveness and

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Diagnosis and treatment of recognised comorbidities in severe asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comorbid condition</strong></td>
<td><strong>Test</strong></td>
</tr>
<tr>
<td>Gastro-oesophageal reflux</td>
<td>3 months empirical therapy trial with proton pump inhibitors or oesophageal pH testing</td>
</tr>
<tr>
<td>Obesity with or without obstructive sleep apnoea syndrome</td>
<td>Polysomnography</td>
</tr>
<tr>
<td>Sinus disease</td>
<td>CT scan, Nasendoscopy</td>
</tr>
<tr>
<td>Depression/anxiety</td>
<td>Evaluation by mental health professional</td>
</tr>
</tbody>
</table>
esoinophilic inflammation—individually contribute to the disease.80 Two other more recent studies identified different clusters of refractory asthma.67 81 The first study distinguished three clusters, one characterised by concordance between asthma symptoms and eosinophilic airway inflammation (early-onset atopic asthma) and two clusters with marked discordance between symptom expression and eosinophilic airway inflammation (obese women with symptom-predominant asthma and late-onset inflammation-predominant asthma).81 The other study identified three clusters of patients with severe refractory asthma: one cluster of obese women with late-onset non-atopic asthma, moderate reductions in FEV1 and frequent oral corticosteroid use to manage exacerbations, and two other clusters with severe airflow obstruction and bronchodilator responsiveness who differed in their ability to attain normal lung function, age of asthma onset, atopic status and use of oral corticosteroids.66

U-BIOPRED
The pan-European project Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED),82 as part of the Innovative Medicines Initiative,83 will push this further by integrating high dimensional data from invasive (bronchial biopsies), non-invasive (blood, sputum, exhaled air) and patient-reported outcomes into distinct phenotype handprints by using an innovative systems biology approach.84 This will enable more detailed phenotyping of adult and paediatric severe asthma and prediction of therapeutic efficacy in view of tailored management.

CONCLUSION
Over the last 15 years there has been a lack of consensus about the definition and diagnosis of severe asthma. Research studies in patients with severe asthma have used different inclusion and exclusion criteria and the nomenclature to describe these patients has been quite confusing. There is now increasing evidence that patients with ‘severe asthma’ form a heterogeneous group, and that many aggravating factors may influence the clinical presentation. For the development of innovative therapies, there is an urgent need for an accurate characterisation of patients with truly severe refractory asthma and for subphenotyping these patients. The U-BIOPRED programme not only reached international consensus on the definition and diagnosis of severe asthma but, more importantly, produced for the first time a stepwise algorithm by which the patient with truly severe refractory asthma may be identified.

Author footnote

Funding
This report was supported by grants from the European Commission Innovative Medicine Initiative Initiative Understanding Severe Asthma, IMI Cal 2008_1 12; final protocol available at http://www.imi.europa.eu.

Competing interests
None.

Contributors
All authors contributed actively to the consensus meeting, revised and changed the manuscript critically and approved the version published. EBH chaired the consensus meeting, developed the framework for the review and wrote the first version of the manuscript. AS, LF, AB, KFC, JV, AHW, SSW, PJ and JC assisted in writing the manuscript and revised the subsequent versions. All participants in the consensus meeting and the U-BIOPRED consortium had the opportunity to review and revise the pre-definitive version of the manuscript. All co-authors were core members of U-BIOPRED work package “Consensus Generation”.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES


7 of 8

Downloaded from http://thorax.bmj.com/ on May 30, 2017 - Published by group.bmj.com
35. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130(1 Suppl):65S–72S.
64. Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED), http://www.ubipred.eu/.
Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)

Elisabeth H Bel, Ana Sousa, Louise Fleming, Andrew Bush, K Fan Chung, Jennifer Versnel, Ariane H Wagener, Scott S Wagers, Peter J Sterk, Chris H Compton and on behalf of the members of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation

Thorax published online November 23, 2010

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2011/05/27/thx.2010.153643

These include:

References
This article cites 77 articles, 13 of which you can access for free at:
http://thorax.bmj.com/content/early/2011/05/27/thx.2010.153643#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Asthma (1782)
Child health (843)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/